Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer

503Citations
Citations of this article
154Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background & Aims: The concept of a CpG island methylator phenotype (CIMP), especially in microsatellite stable colon cancer, is not accepted universally. We therefore evaluated a large population-based sample of individuals with colon cancer and used univariate and multivariate analyses of CIMP with clinicopathologic variables and tumor mutations to determine the biologic relevance of this phenotype. Methods: A total of 864 tumors from individuals with colon cancer from Utah and Northern California were evaluated by methylation-specific polymerase chain reaction of CpG islands in hMLH1, methylated in tumors (MINT) 1, MINT 2, MINT 31, and CDKN2A (p16). CIMP high was defined as methylation at 2 or more of these loci. The BRAF V600E mutation was determined by sequencing. Microsatellite instability had been determined previously. Results: In a multivariate analysis of microsatellite stable tumors, CIMP high was related significantly to the V600E BRAF mutation (odds ratio, 39.52; 95% confidence interval, 11.44-136.56), KRAS2 mutations (odds ratio, 2.22; 95% confidence interval, 1.48-3.34), older age (P trend = .03), and increased stage (P trend = .03), and these tumors were less likely to be located in the distal colon (odds ratio, .42; 95% confidence interval, .27-.65). CIMP-high unstable tumors also were more likely to have the V600E BRAF mutation, be located proximally, and occur in older individuals (in univariate analyses). However, CIMP-high unstable tumors were significantly more likely than their stable counterparts to be KRAS2 wild type, TP53 wild type, poorly differentiated, proximally located, occur at lower stages, and have the BRAF V600E mutation (64.1% vs 17.6%). Conclusions: The evaluation of a large, population-based sample strongly supports the biologic relevance of CIMP in colon cancer. However, the presence or absence of microsatellite instability has a major effect on the expression of this phenotype. © 2005 by the American Gastroenterological Association.

References Powered by Scopus

Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands

5334Citations
N/AReaders
Get full text

CpG island methylator phenotype in colorectal cancer

2237Citations
N/AReaders
Get full text

RAF/RAS oncogenes and mismatch-repair status

1123Citations
N/AReaders
Get full text

Cited by Powered by Scopus

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

1655Citations
N/AReaders
Get full text

Classification of colorectal cancer based on correlation of clinical, morphological and molecular features

1180Citations
N/AReaders
Get full text

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

1136Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Samowitz, W. S., Albertsen, H., Herrick, J., Levin, T. R., Sweeney, C., Murtaugh, M. A., … Slattery, M. L. (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology, 129(3), 837–845. https://doi.org/10.1053/j.gastro.2005.06.020

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 66

63%

Researcher 28

27%

Professor / Associate Prof. 7

7%

Lecturer / Post doc 3

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 63

56%

Agricultural and Biological Sciences 29

26%

Biochemistry, Genetics and Molecular Bi... 17

15%

Engineering 4

4%

Save time finding and organizing research with Mendeley

Sign up for free